Videos

A dive into the manifestation of the rare skin condition, and the impactful role of dermatologists in diagnosing it early.

At HiD 2022, Dr. Budoff discusses the use and utility of coronary calcium scoring for risk stratification

Savanna Perry, PA-C, discussed the challenge of standing out over influencers and estheticians regarding clinical dermatology insight, and the unique offerings of different platforms.

Savanna Perry, PA-C, founder of The PA Platform, discusses the strategies and goals that go into building an online audience as a healthcare professional.

Dr. Cohen details the latest study from Yale, which indicated that women from lichen sclerosus had increased risk of developing depression and anxiety.

Dr. Gadani often suggests patients eat smaller meals and do not eat too close to bedtime.

Dr. Lisa Arkin speaks to how evidence-based, expert opinion-led consensus treatment plans for scleroderma can help change the way patients and providers approach the disease.

Dr. Cordoro speaks on the prevalence of variants of scleroderma in children, and how provides can better recognize and treat the disease in pediatric populations.

Mark Blumberg, MD, discusses his laboratory's particular interest in early REM sleep movement, and its potential impact on neurological disorders.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

In recent years more and more biologics have come on the market for the treatment of IBD.

A Montefiore residency director explains the impact of engaging with communities to improve mental health care capability.

In data presented at DDW, there was no evidence found showing biologics result in an increased risk of developing malignancies for patients with IBD and PSC.

Montefiore's Carol A. Bernstein, MD, discusses the role of psychiatry specialists in discerning their colleagues' need for mental health care or resolutions to burnout.

New data suggests there is no connection between ustekinumab and the risk of malignancies.

There are several companies preparing new treatments for recurrent C difficile infections.

There are several potential treatments on the horizon for C difficile infections.

Gina Poe, PhD, discusses the potential role of beta blockers in treating psychiatric illness-related sleep, as well as the specific benefit of melatonin.

NIDA research director Carlos Blanco-Jerez, MD, PhD, reviews how stigma, language barriers and digital health create disparate outcomes in mentally-ill Hispanic patients.

Lois Choi-Kain, MD, MEd, discusses her field's interest in improving the modern diagnosis and evidenced-based treatment of personality disorders.

The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.

Patients treated with ustekinumab are not at an increased risk of malignancies.

The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.

Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.

The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.

There are several live microbiota therapeutics in development, including RBX2660.

Data show the safety profile of Ustekinumab in long-term IBD pooled safety dataset was found favorable among bionaive patients.

The treatment has previously been approved by the FDA for the treatment of ulcerative colitis.